Bioequivalence Study Between "DA-5215 Tab" and "DA-5215-R Tab"

NCT ID: NCT05376085

Last Updated: 2022-05-17

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-05-31
• Study Completion Date: 2022-07-31

Brief Summary

An Open-Label, Randomized, Fasting Condition, Single-dose, Cross-over Study to Evaluate the Bioequivalence between "DA-5215 Tab" and "DA-5215-R Tab" in Healthy Volunteers

Detailed Description

1. Study design: An open-Label, randomized, 2-sequence, 2-period, fasting condition, single-dose, per oral, cross-over study

2. Administration method:

The subject should maintain a minimum of 10 hours of fasting status before administration, and give an oral dose of 1 tablet (DA-5215 or DA-5215-R) with 150 mL of water at around 8 a.m. on 1D of each period. The subject should not chew or break the drug, but should swallow in whole with water. The difference in administration time between the subjects is about one minute apart, considering the blood collection time.

3. Wash out period: at least 7 days

4. Blood collection time: Before the administration,15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 hours after the administration (total 16 times)

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

RT

T: "DA-5215" R: "DA-5215-R"

Group Type: EXPERIMENTAL

DA-5215 Tab

Intervention Type: DRUG

single oral administration of 1 tablet of "DA-5215 Tab" with 150mL water

DA-5215-R Tab

Intervention Type: DRUG

single oral administration of 1 tablet of "DA-5215-R Tab" with 150mL water

TR

T: "DA-5215" R: "DA-5215-R"

Group Type: EXPERIMENTAL

DA-5215 Tab

Intervention Type: DRUG

single oral administration of 1 tablet of "DA-5215 Tab" with 150mL water

DA-5215-R Tab

Intervention Type: DRUG

single oral administration of 1 tablet of "DA-5215-R Tab" with 150mL water

Interventions

DA-5215 Tab

single oral administration of 1 tablet of "DA-5215 Tab" with 150mL water

Intervention Type: DRUG

DA-5215-R Tab

single oral administration of 1 tablet of "DA-5215-R Tab" with 150mL water

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. A person who aged 19 or older at the time of screening

2. BMI of 18 to 30 (BMI calculation: kg/m2)

• Males weighing 50kg or more, Females weighing 45kg or more

3. No congenital or chronic diseases or pathological symptoms

4. A person who is judged to be suitable for the study by the investigator based on the clinical laboratory examination

5. A person who agreed to use contraception from the first administration of IP to a week after the last administration of IP

6. A person who has fully understood the contents of the consent form for the study and signed the consent form voluntarily and recorded the date of signature

Exclusion Criteria

1. A person who has taken a drug that significantly induces (e.g., barbital) or inhibits the drug metabolic enzyme within 30 days prior to the first administration of IP

2. A person who has participated in other clinical trials within six months prior to the first administration of the IP

3. A person who has had whole blood transfusion within 8 weeks or the apheresis within 2 weeks before the first administration of IP

4. A person who has medical history of gastric resection that can affect the drug absorption

5. A person with a history of regular alcohol intake within a month prior to the first administration of the IP:

• Male: More than 21 cups/week
• Female: More than 14 cups/week (1 cup: 50 ml of soju, 250 ml of beer, 30ml of spirits)

6. A person who is hypersensitive to any of the IP components

7. A person who has medical history of mental disease

8. A person who is judged not to be suitable for the study by the investigator

9. Lactating or possibly pregnant women

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Dong-A ST Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

SeungHyun Kang, Ph.D

Role: PRINCIPAL_INVESTIGATOR

H Plus Yangji Hospital

Locations

H Plus Yangji Hospital

Seoul, , South Korea

Countries

South Korea

Central Contacts

SeungHyun Kang, Ph.D

Role: CONTACT

juspa@naver.com

82-070-4665-9490

Facility Contacts

SeungHyun, Kang

Role: primary

juspa@naver.com

82-070-4665-9490

Other Identifiers

DTC21-IP064

Identifier Type: -

Identifier Source: org_study_id